AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
AMAM
Delisted
AMAM was delisted on the 6th of March, 2024.
30 hedge funds and large institutions have $331M invested in Ambrx Biopharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 5 closing their positions.
Holders
30
Holders Change
+12
Holders Change %
+66.67%
% of All Funds
0.48%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.06%
New
17
Increased
9
Reduced
4
Closed
5
Calls
$13.1M
Puts
$2.3M
Net Calls
+$10.8M
Net Calls Change
+$11M
Top Buyers
1 |
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
|
$75.8M |
2 |
CC
2
Commodore Capital
New York
|
$42.8M |
3 |
3
D.E. Shaw & Co
New York
|
$35.1M |
4 |
DGM
4
Darwin Global Management
St. Helier,
Jersey
|
$101M |
5 |
VA
5
VR Adviser
New York
|
$29.4M |